Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sugemalimab consolidation in Stage III NSCLC
NCT03728556Phase 3Completed
- Sponsor
- CStone Pharmaceuticals
- Start
- Oct 2018
- Primary completion
- Apr 2023
- Modality
- Immune Checkpoint Inhibitors, Antibody Conjugates, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Sugemalimab with Placebo (2 arms). Primary endpoint: Progression-Free Survival at 30 months. Started Oct 2018; status: completed.
02
Drugs
sugemalimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03728556.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03728556.